2907782-78-7

AD1058 is an orally active, selective, and blood-brain barrier permeable inhibitor of ATR. AD1058 exhibits in vivo anticancer activity, inhibiting cell proliferation, disrupting the cell cycle, and inducing Apoptosis. AD1058 can be utilized in research on brain and central nervous system metastases stemming from advanced solid tumors[1].

ATR: 1.6 nM (IC₅₀); mTOR: 45.83 nM (IC₅₀); ARK5: 7314.00 nM (IC₅₀); LCK: 2594.00 nM (IC₅₀)

[1] Liu Z, Jiang K, et al. Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies. J Med Chem. 2024 Aug 8;67(15):12735-12759. DOI:10.1021/acs.jmedchem.4c00734